Amjevita (adalimumab-atto) is a biosimilar to the widely used biologic Humira. A biosimilar is a biologic medication that is highly similar to an already approved biologic drug (in this case, Humira), with no clinically meaningful differences in safety, purity, or potency.

Amjevita works by targeting tumor necrosis factor-alpha (TNF-α), a protein involved in systemic inflammation. By blocking TNF-α, Amjevita helps control abnormal immune responses seen in autoimmune diseases.

Approved uses include treatment of:

• Rheumatoid arthritis

• Psoriatic arthritis

• Ankylosing spondylitis

• Plaque psoriasis

• Crohn’s disease

• Ulcerative colitis

• Juvenile idiopathic arthritis

• Hidradenitis suppurativa

Administration:

• Subcutaneous injection (under the skin), usually via a prefilled syringe or autoinjector pen.

• Dosing schedule depends on the condition being treated (weekly or biweekly is common).

Common side effects:

• Injection site reactions

• Headache

• Respiratory infections

• Nausea

Serious risks:

• Increased risk of serious infections (e.g., tuberculosis)

• Certain cancers

• Hepatitis B reactivation

Patients must be screened for TB and hepatitis B before starting Amjevita.